LaiMei Pharmaceutical: Guangtou Group plans to increase capital and expand shares in Guangtou JinKong with 25.94% of Zhongheng Group shares

LaiMei Pharmaceutical announced that its indirect controlling shareholder GuangTou Group intends to increase the capital of GuangTou JinKong, a holding subsidiary of GuangTou Group, by using its 859 million shares of Zhongheng Group. This transaction falls under the change of state-owned equity under the same control. After the transaction is completed, GuangTou JinKong will become the indirect controlling shareholder of the company, while Zhongheng Group will remain the direct controlling shareholder, and the Guangxi State-owned Assets Supervision and Administration Commission will still be the actual controller of the company. The above-mentioned equity change is still in the planning stage and needs to go through the state-owned assets approval process and related legal procedures